Equinor ASA: Completed share capital reduction GlobeNewswire July 02, 2025 On 14 May 2025, the annual general meeting in Equinor ASA (OSE: EQNR, NYSE: EQNR) decided that the company's share capital shall be reduced by NOK 589,934,295 from NOK 6,981,953,075 to NOK 6,392,018,780, through cancellation and redemption of a total of 235,973,718 shares. The creditor […]
Today, the Republic of Chile (“Chile”) announced the results of its exchange offer for Euro-denominated notes announced on June 24, 2025 (the “Invitation”), as described below. Capitalized terms used and not defined herein shall have the meaning assignedto them in the invitation materials. In connection with the Invitation, pursuant to which Chile invited holders of
Blockdaemon, the leading U.S. headquartered institutional-grade crypto infrastructure company, announced today the appointment of Alex Zinder as Chief Product Officer (CPO). In this role, Zinder will lead overall product development, sharpen product vision, strengthen execution rhythm, and elevate Blockdaemon's platform offerings which include staking, DeFi, MPC wallets and vaults, nodes, and APIs. https://mma.prnewswire.com/media/2714566/Blockdaemon_Primary_Purple_Logo.jpg With over
(NYSE MKT:CMCL),(LSE – AIM:CMCL),(LSE:CMCL.L),(LSE:CMCL.LN), ST HELIER, Jersey, July 02, 2025 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or “the Company”) (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) announces that it received notification on June 30, 2025 from BlackRock, Inc. that on June 27, 2025 it had crossed a threshold for notification of a relevant
(Euronext Amsterdam:SHELL),(LSE:SHEL),(NYSE:SHEL), Due to EY non-compliance with audit partner rotation rules, Shell to update 2023 and 2024 Form 20-Fs; financial statements remain unchanged London, July 2, 2025 – Ernst & Young LLP (“EY”) has advised Shell plc that, for the years ended December 31, 2023 and 2024, EY was not in compliance with the SEC
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646 participant visits, including both Type 2 diabetic patients and healthy volunteers Magnetohydrodynamic (MHD) technology achieves 11.5% MARD in extensive clinical performance study using mass-manufactured devices, validating commercial-scale production capability Helsinki, Finland – July 2, 2025
(Paris:OSE), OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that following the hearing on June 24th, 2025, the President of the Nantes Commercial Court rejected, pursuant to an order dated July 1, 2025, the motions brought by the group
Due to EY non-compliance with audit partner rotation rules, Shell to update 2023 and 2024 Form 20-Fs; financial statements remain unchanged GlobeNewswire July 02, 2025 Due to EY non-compliance with audit partner rotation rules, Shell to update 2023 and 2024 Form 20-Fs; financial statements remain unchanged London, July 2, 2025 – Ernst & Young LLP
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch GlobeNewswire July 02, 2025 GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646 participant visits, including both Type 2 diabetic patients and healthy volunteers Magnetohydrodynamic (MHD) technology achieves 11.5% MARD
OSE Immunotherapeutics met a jour l'information sur les procedures en cours GlobeNewswire July 02, 2025 OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that following the hearing on June 24th, 2025, the President of the Nantes Commercial Court rejected,